Cargando…

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer

The sequential doxorubicin → CMF (CMF=cyclophosphamide, methotrexate, fluorouracil) regimen has never been compared to CMF in a randomised trial. The role of adding goserelin and tamoxifen after chemotherapy is unclear. In all, 466 premenopausal node-positive patients were randomised to: (a) CMF × 6...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Placido, S, De Laurentiis, M, De Lena, M, Lorusso, V, Paradiso, A, D'Aprile, M, Pistillucci, G, Farris, A, Sarobba, M G, Palazzo, S, Manzione, L, Adamo, V, Palmeri, S, Ferraù, F, Lauria, R, Pagliarulo, C, Petrella, G, Limite, G, Costanzo, R, Bianco, A R
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2005
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362097/ https://www.ncbi.nlm.nih.gov/pubmed/15668708 http://dx.doi.org/10.1038/sj.bjc.6602355

Ejemplares similares

CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study).
por: De Placido, S., et al.
Publicado: (1995)

Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life.
por: Fraser, S. C., et al.
Publicado: (1993)

The Assessment of Response to Adjuvant Chemotherapy with CMF in Triple Negative Breast Cancer
por: Mousavi, Seyyed AsadoLah, et al.
Publicado: (2013)

Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials
por: Earl, H M, et al.
Publicado: (2012)

Block sequential adriamycin CMF – optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?
por: Cameron, D A, et al.
Publicado: (2002)

Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer
por: Erselcan, T, et al.
Publicado: (2000)

Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer
por: Cameron, D A, et al.
Publicado: (2003)

Oxidation of 5-Chloromethylfurfural (CMF) to 2,5-Diformylfuran (DFF)
por: Vicente, Ana I., et al.
Publicado: (2017)

Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF
por: Poikonen, P, et al.
Publicado: (1999)

Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF
por: Colleoni, M, et al.
Publicado: (2002)

CMF, Chaikin money flow: changes anticipating price reversal
por: Thomsett, Michael C
Publicado: (2011)

AO Craniomaxillofacial Surgery (AO CMF): A World of Opportunities
por: Kadam, Dinesh
Publicado: (2020)

Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer.
por: O'Byrne, K. J., et al.
Publicado: (1998)

BCL2 is a predictive marker of adjuvant CMF regimen in triple-negative breast cancer patients
por: Bouchalova, K, et al.
Publicado: (2011)

Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer
por: Gwak, Geumhee, et al.
Publicado: (2011)

Response of a chemo-resistant triple-negative breast cancer patient to a combination of p62-encoding plasmid, Elenagen, and CMF chemotherapy
por: Ponomarenko, Dmitry M., et al.
Publicado: (2020)

Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience
por: De Maio, Ermelinda, et al.
Publicado: (2005)

Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis
por: Yu, Ke-Da, et al.
Publicado: (2013)

The cell density factor CMF regulates the chemoattractant receptor cAR1 in Dictyostelium
Publicado: (1996)

Efficient One-Pot Synthesis of 5-Chloromethylfurfural (CMF) from Carbohydrates in Mild Biphasic Systems
por: Gao, Wenhua, et al.
Publicado: (2013)

Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer
por: Bos, A M E, et al.
Publicado: (2000)

The computational prediction of drug-disease interactions using the dual-network L(2,1)-CMF method
por: Cui, Zhen, et al.
Publicado: (2019)

Mutation of the ALBOSTRIANS Ohnologous Gene HvCMF3 Impairs Chloroplast Development and Thylakoid Architecture in Barley
por: Li, Mingjiu, et al.
Publicado: (2021)

Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breast
por: Harper-Wynne, C, et al.
Publicado: (1999)

A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.
por: Jodrell, D. I., et al.
Publicado: (1991)

A Comparison of 5-HT3 Receptor Antagonist and Metoclopramide in the Patients Receiving Chemotherapeutic Regimens Including CMF, CAF and CHOP
por: Anvari, Kazem, et al.
Publicado: (2015)

Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study
por: De Placido, S, et al.
Publicado: (2005)

A divergent approach for the synthesis of (hydroxymethyl)furfural (HMF) from spent aromatic biomass-derived (chloromethyl)furfural (CMF) as a renewable feedstock
por: Singh, Mangat, et al.
Publicado: (2020)

The G Protein Biased Small Molecule Apelin Agonist CMF-019 is Disease Modifying in Endothelial Cell Apoptosis In Vitro and Induces Vasodilatation Without Desensitisation In Vivo
por: Read, Cai, et al.
Publicado: (2021)

The affect of goserelin on the QoL of women having chemotherapy for EBC: Results from the OPTION trial
por: R, Leonard, et al.
Publicado: (2020)

Reinduction of Hormone Sensitivity to Goserelin following Chemotherapy with Vinorelbine in Castration-Resistant Prostate Cancer
por: Grenader, Tal, et al.
Publicado: (2010)

Comment on Gao, W., et al. “Efficient One-Pot Synthesis of 5-Chloromethylfurfural (CMF) from Carbohydrates in Mild Biphasic Systems”, Molecules 2013, 18, 7675-7685
por: Mascal, Mark
Publicado: (2014)

Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer
por: Cheng, Tsui Fen, et al.
Publicado: (2012)

Conocimiento de los médicos de primer nivel sobre escrutinio para cáncer de mama después de un taller informativo en la CMF- ISSSTE Veracruz. : /
por: Ramírez Sánchez, Patricia
Publicado: (2014)

Correction: Gao, W., et al. Efficient One-Pot Synthesis of 5-Chloromethyl-furfural (CMF) from Carbohydrates in Mild Biphasic Systems. Molecules 2013, 18, 7675-7685
por: Gao, Wenhua, et al.
Publicado: (2014)

Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial
por: Maggi, R, et al.
Publicado: (2006)

Adjuvant chemotherapy for operable breast cancer: old vs new schema
por: Valagussa, P, et al.
Publicado: (2005)

Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover
por: Wilson, Caroline, et al.
Publicado: (2016)

Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur–uracil with CMF (N·SAS-BC 01 trial and CUBC trial)
por: Ohno, Shinji, et al.
Publicado: (2020)

Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial
por: Li, Jian-wei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_102t48sj0fmpljh7cfpmhpq6u6